Novus Reports Q3 Earnings: Highlighting Self-Funded Growth and Investor Value

MIAMI, FL – November 12, 2025 – Novus Acquisition and Development Corp. (OTC Markets: NDEV), a carrier and leader in comprehensive health insurance plans that integrate cannabis, highlights its strategy for achieving organic growth without external financing, centered on financial discipline and efficiency. 

This reporting period highlights Novus's strategy, which is centered on the company's Benefit Monetization Ratio (BMR). This metric is recommended as a crucial tool for investors to assess the company's ability to create shareholder value. A fundamental financial argument is made regarding the company's potential undervaluation based on the following:

Financial and Operational Highlights (9 Months Ended September 30, 2025)

• Gross Revenue Growth: Gross Revenue increased by 8.85% compared to the same period in 2024, demonstrating consistent top-line growth.

• Profitability: Net Revenue growth is tied to an 18.1% increase in EBITDA, indicating improved operational efficiency and profitability margins.

• Cash Position: Cash and Cash Equivalents rose 7.2% year over year, supporting the claim of self-funded growth.

Capital Structure and Investor Protection

• No Issuances: The number of issued and outstanding shares remained unchanged

• Non-Dilutive Growth: The company emphasizes its commitment to shareholder value by noting that no insiders have sold shares in the past three years, aligning insider interests with long-term company performance.

• Simplified Debt: No outstanding or issued convertible notes simplify the capital structure and eliminate the risk of future common stock dilution from debt conversion.

• Vendor Share Leak-Out Provision: A contractual cap on vendor stock sales (limited to 15% of the average daily trading volume over the preceding 30 days) is designed to mitigate market impact and prevent sudden selling pressure on the stock price.

• CEO Loan Transparency: The debt obligation to CEO Frank Labrozzi is clearly disclosed ($168,789) and, importantly, does not include an equity conversion provision, further preventing any unexpected dilution.

Frank Labrozzi, CEO, states, "Novus is advancing a vision where cannabis is positioned as a core component of mainstream healthcare, utilizing strategic procurement and compliance loopholes to integrate it into comprehensive health plans. By securing significant cost reductions on nearly 25,000 generic and brand-name pharmaceuticals, we are enhancing affordability and access across our entire prescription drug program. This strategic move enables us to integrate a complete prescription drug plan, including cannabis-based therapies, into our online platform. We are unlocking new avenues for market growth by making cannabis treatments more accessible and affordable, with premiums for these treatments tax-deductible in Health Savings Accounts. This initiative represents a pivotal growth catalyst for Novus and positions us to capture significant value in this rapidly expanding sector."

About Novus Cannabis MedPlan: Novus Cannabis MedPlan is a premier provider of medical cannabis supplemental health plans, dedicated to enhancing the accessibility and affordability of medical cannabis for patients nationwide. Through a robust network of licensed dispensaries, qualified physicians, and wellness providers, Novus delivers comprehensive membership benefits structured to support patient health journeys with transparency, dedicated care, and notable financial benefits.

Further Research:

• Financial Filings: Click Here

• Quote: Click Here

• Investor's Page: Click Here 

Forward-Looking Statements

This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is a not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.

Investor Contact Information

Investor Website

855-228-7355 

Email: [email protected]